Online Sharing for Head & Neck Cancer Support
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Head and neck cancer patients often experience significant anxiety and depression during radiation therapy, which can affect their quality of life and treatment adherence. However, traditional psychological support is limited by resource constraints and accessibility. This study aims to evaluate whether a mobile application based on social sharing and peer interaction can improve psychological distress in patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy. This is a prospective, randomized, parallel-group, open-label trial. A total of 120 participants will be randomly assigned in a 1:1 ratio to either the immediate intervention group or a waitlist control group. Participants in the intervention group will use a dedicated app featuring daily sharing, peer interaction (anonymous comments, likes, private messaging), psychoeducational resources, and reminders. The control group will receive a printed psychoeducational booklet during the initial phase and will gain access to the app after the primary endpoint assessment. The primary outcome is the change in anxiety score (HADS-A) from baseline to completion of radiotherapy. Secondary outcomes include depression scores (HADS-D), radiotherapy interruption rate, app engagement, and severe psychological distress prevalence. Exploratory outcomes include quality of life (EORTC QLQ-C30, H\&N35), readmission rate, adverse event severity (CTCAE v5.0), and biological markers (e.g., cortisol, IL-6, CRP). The study is expected to run from April 2026 to August 2027. Findings may inform scalable digital psychosocial interventions for cancer patients.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat
- •Oczekiwana długość życia co najmniej 6 miesięcy
- •Potwierdzony rozpoznaniem rak płaskonabłonkowy głowy i szyi bez przerzutów do odległych narządów
- •Zaplanowana radioterapia lub radioterapia po operacji
- •Dobry ogólny stan zdrowia (skala ECOG 0-2)
- •Umiejętność czytania i wypełniania ankiet
- •Dostęp do smartfona lub tabletu
- •Płynnie mówiący i czytający po chińsku
✗ Disqualifies
- •Inne nowotwory (poza bazalioma lub rakiem szyjki macicy w stadium początkowym)
- •Wcześniejsza radioterapia głowy i szyi
- •Historia problemów psychiatrycznych lub stosowanie leków psychotropowych
- •Bezwzględne przeciwwskazania do radioterapii głowy i szyi
- •Niekontrolowane choroby ogólnoustrojowe (cukrzyca, niewydolność serca, schorzenia płuc)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
West China Hospital, Sichuan University
Chengdu, China
Trial contact
Xingchen Peng
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.